| Description |
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces Apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research[1].
|
| Related Catalog |
|
| Target |
TRAIL-R2[1]
|
| In Vitro |
The combination of Cisplatin (HY-17394) with Lexatumumab synergistically inhibits the cell growth and enhanced apoptotic death[1]. Lexatumumab (0-10 µg/ml, 72 h) induces various degrees of cell death in the different melanoma cell lines[2]. Cell Viability Assay[2] Cell Line: Melanoma cell lines Concentration: 0.01, 0.1, 1.0 and 10.0 µg/ml Incubation Time: 72 h Result: Induced various degrees of cell death in the different cell lines.
|
| In Vivo |
Lexatumumab (10 mg/kg, i.v., twice a week) increases antitumor effect in vivo when combined with Dacarbazine (HY-B0078)[2]. Animal Model: FEMX-1 xenografts mice[2] Dosage: 10 mg/kg, 10 mg/kg+Dacarbazine (62.5 mg/kg once a week, i.p. injection) Administration: i.v., twice a week Result: Increased antitumor effect in vivo when combined with Dacarbazine (HY-B0078). Induced cleavage of livin into its truncated, proapoptotic form, a compound previously shown to accelerate apoptosis.
|
| References |
[1]. Belyanskaya LL, et al. Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Mol Cancer. 2007 Oct 22;6:66. [2]. Engesæter B, et al. Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma. PLoS One. 2012;7(9):e45492.
|
